Published • loading... • Updated
NRx Begins Ketamine Production Ahead of FDA Decision
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NRx Begins Ketamine Production Ahead of FDA Decision
WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) has placed its first commercial manufacturing order for a preservative-free ketamine product ahead of a potential U.S. approval expected under the Generic Drug User Fee Act process this summer. The order follows stability testing on more than three registration batches and completion of third-party Good Manufacturing Practice audits at the company’s U.S.-based manufacturing facility. NRx is als…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
